- 61.3k views
Critical Care Procedures Done in COVID ICU
Acute respiratory distress syndrome (ARDS), septic shock, thromboembolic disease, hepatic and/or renal dysfunction, central nervous system disease, and worsening of underlying comorbidities are just a few of the serious illnesses that COVID-19 can advance to in both adults and children. In addition, the multisystem inflammatory syndrome in adults (MIS-A), which can cause catastrophic disease, can develop weeks or months following SARS-CoV-2 infection. These Guidelines' initial advice for treating critically unwell people with COVID-19 was largely drawn from knowledge of other causes of sepsis and respiratory failure. 1 However, there is currently a rapidly expanding corpus of research on the management of severely ill COVID-19 patients. In the critical care unit (ICU), treating COVID-19 patients frequently necessitates controlling underlying conditions.
About the Speaker
Dr. Aklesh Tandekar
CRITICAL CARE SPECIALIST MD, EDIC, IDCCM, FIMSA, DA, FCPS, FISCCM
Upcoming Case Discussions
H. pylori Treatment with PYELRA®: Best Practices
PYLERA® is a medication used for the treatment of Helicobacter pylori (H. pylori) infection, a common cause of stomach ulcers and gastritis. It contains a combination of three active ingredients: bismuth subcitrate potassium, metronidazole, and tetracycline. This combination works synergistically to eradicate H. pylori bacteria and reduce associated symptoms. Treatment with PYLERA® typically involves taking multiple capsules four times a day for a specified duration, as prescribed by a healthcare provider. It is important to follow the treatment regimen as directed and to discuss potential side effects
Management of Pulmonary Fibrosis
Pulmonary fibrosis is diagnosed through a combination of medical history, imaging studies (like high-resolution CT scans), pulmonary function tests, and sometimes lung biopsies. Treatment often involves medications such as corticosteroids, immunosuppressants (like azathioprine or mycophenolate), and antifibrotic drugs (such as pirfenidone or nintedanib) to slow disease progression and manage symptoms.Supplemental oxygen therapy is commonly prescribed to relieve shortness of breath and improve oxygen levels in the blood. This program combines exercise training, education, and breathing techniques to improve overall physical condition and quality of life. Patients with pulmonary fibrosis should receive vaccinations against influenza and pneumococcal pneumonia to reduce the risk of respiratory infections. In severe cases, lung transplantation may be considered for eligible patients to improve survival and quality of life. Treatments like nutritional support, psychological counseling, and palliative care can provide comprehensive support and symptom management.
Ulcerative colitis: Diagnosis & Management
Ulcerative colitis is diagnosed through a combination of clinical evaluation, laboratory tests, imaging studies, and endoscopic examination of the colon. Key diagnostic tests include stool studies to rule out infections, blood tests for inflammatory markers like C-reactive protein and fecal calprotectin, and colonoscopy with biopsy to visualize the colon and confirm the diagnosis. Imaging studies like CT scans or MRI may be used to assess disease severity and complications such as toxic megacolon or perforation. Management of ulcerative colitis involves a step-wise approach, starting with anti-inflammatory medications like aminosalicylates for mild to moderate disease.Immunosuppressants such as corticosteroids, thiopurines, or biologics (e.g., anti-TNF agents) are used for moderate to severe disease or if patients do not respond to first-line therapy. Regular monitoring of disease activity through symptom assessment, blood tests, and endoscopic evaluation is crucial for disease management and to prevent complications.
Fluid Management and Hemodynamic Optimization
Fluid management and hemodynamic optimization are crucial components of patient care in various clinical settings, particularly in critical care, perioperative care, and the management of sepsis and shock. The goal of fluid management is to achieve an optimal balance between fluid administration and removal, ensuring adequate tissue perfusion while minimizing complications associated with fluid overload or depletion. This involves assessing the patient's fluid status, monitoring hemodynamic parameters such as blood pressure, heart rate, cardiac output, and oxygen delivery, and tailoring fluid therapy accordingly. Strategies for hemodynamic optimization may include the use of fluid resuscitation, vasopressors, inotropes, and other interventions aimed at maintaining organ perfusion and function. However, it's essential to individualize treatment based on the patient's specific condition, comorbidities, and response to therapy, while also considering potential risks such as pulmonary edema, renal impairment, and tissue ischemia. Effective fluid management and hemodynamic optimization require a multidisciplinary approach, close monitoring, and ongoing reassessment to optimize patient outcomes while minimizing complications.
Micronutrient Deficiencies
Micronutrient deficiencies refer to insufficient intake or absorption of essential vitamins and minerals, including vitamin A, vitamin D, iron, iodine, and zinc, among others. These deficiencies can lead to a range of health problems, such as anemia, impaired immune function, poor bone health, and developmental delays. Micronutrient deficiencies are often prevalent in populations with limited access to diverse and nutritious foods, as well as in individuals with certain medical conditions or dietary restrictions. Addressing micronutrient deficiencies requires a multifaceted approach, including dietary diversification, food fortification, supplementation, and public health interventions aimed at improving access to nutritious foods and promoting healthy eating habits.
Author Post
Impact
+
Talks
+
webinar
+
no.of registrations
One liner about speaker
Why is speaker relevant?
Dr. Aklesh Tandekar's Talks on Assimilate
- 0
Acute respiratory distress syndrome (ARDS), septic shock, thromboembolic disease, hepatic and/or renal dysfunction, central nervous system disease, and worsening of underlying comorbidities are just a few of the serious illnesses that COVID-19 can advance to in both adults and children. In addition, the multisystem inflammatory syndrome in adults (MIS-A), which can cause catastrophic disease, can develop weeks or months following SARS-CoV-2 infection. These Guidelines' initial advice for treating critically unwell people with COVID-19 was largely drawn from knowledge of other causes of sepsis and respiratory failure. 1 However, there is currently a rapidly expanding corpus of research on the management of severely ill COVID-19 patients. In the critical care unit (ICU), treating COVID-19 patients frequently necessitates controlling underlying conditions.
- 0
Acute respiratory distress syndrome (ARDS), septic shock, thromboembolic disease, hepatic and/or renal dysfunction, central nervous system disease, and worsening of underlying comorbidities are just a few of the serious illnesses that COVID-19 can advance to in both adults and children. In addition, the multisystem inflammatory syndrome in adults (MIS-A), which can cause catastrophic disease, can develop weeks or months following SARS-CoV-2 infection. These Guidelines' initial advice for treating critically unwell people with COVID-19 was largely drawn from knowledge of other causes of sepsis and respiratory failure. 1 However, there is currently a rapidly expanding corpus of research on the management of severely ill COVID-19 patients. In the critical care unit (ICU), treating COVID-19 patients frequently necessitates controlling underlying conditions.
- 0
Acute respiratory distress syndrome (ARDS), septic shock, thromboembolic disease, hepatic and/or renal dysfunction, central nervous system disease, and worsening of underlying comorbidities are just a few of the serious illnesses that COVID-19 can advance to in both adults and children. In addition, the multisystem inflammatory syndrome in adults (MIS-A), which can cause catastrophic disease, can develop weeks or months following SARS-CoV-2 infection. These Guidelines' initial advice for treating critically unwell people with COVID-19 was largely drawn from knowledge of other causes of sepsis and respiratory failure. 1 However, there is currently a rapidly expanding corpus of research on the management of severely ill COVID-19 patients. In the critical care unit (ICU), treating COVID-19 patients frequently necessitates controlling underlying conditions.